Combining probiotics and an angiotensin-II type 1 receptor blocker has beneficial effects on hepatic fibrogenesis in a rat model of non-alcoholic steatohepatitis. 3

• Material Type: 博士論文
• Title: Combining probiotics and an angiotensin-II type 1 receptor blocker has beneficial effects on hepatic fibrogenesis in a rat model of non-alcoholic steatohepatitis.
• Volume: 49 3
• Author/Editor: Sawada, Yasuhiko; Kawaratani, Hideto; Kubo, Takuya; Fujinaga, Yukihisa; Furukawa, Masanori; Saikawa, Soichiro; Sato, Shinya; Seki, Kenichiro; Takaya, Hiroaki; Okura, Yasushi; Kaji, Kosuke; Shimozato, Naotaka; Mashitani, Tsuyoshi; Kitade, Mitsuteru; Moriya, Kei; Namisaki, Tadashi; Akahane, Takemi; Mitoro, Akira; Yamao, Junichi; Yoshiji, Hitoshi
• Author Heading: Sawada, Yasuhiko; Kawaratani, Hideto; Kubo, Takuya; Fujinaga, Yukihisa; Furukawa, Masanori; Saikawa, Soichiro; Sato, Shinya; Seki, Kenichiro; Takaya, Hiroaki; Okura, Yasushi; Kaji, Kosuke; Shimozato, Naotaka; Mashitani, Tsuyoshi; Kitade, Mitsuteru; Moriya, Kei; Namisaki, Tadashi; Akahane, Takemi; Mitoro, Akira; Yamao, Junichi; Yoshiji, Hitoshi
• Publication, Distribution, etc.: Wiley
• Publication Date: 2019-03; 49 3
• Publication Date (W3CDTF): 2019-03
• Alternative Title: ラット非アルコール性脂肪肝炎モデルに対するプロバイオティクスとアンギオテンシンⅡ受容体拮抗薬併用療法の肝線維化に対する有効性
• Periodical title: Hepatology research
• Pages: 284-295
• ISSN (Periodical Title): 13866346
• Degree Grantor: 奈良県立医科大学
• Date Granted: 2020-09-30
• Date Granted (W3CDTF): 2020-09-30
• Dissertation Number: 乙第1465号
• Degree Type: 博士（医学）
• Conferring No. (Dissertation): 乙第1465号
• Text Language Code: eng
• Subject Heading: angiotensin‐II type 1 receptor blocker (ARB); hepatic fibrosis; intestinal tight junction; non‐alcoholic steatohepatitis; probiotic
• Target Audience: 一般
• Note (General): type:Thesis; Aim: Intestinal endotoxin is important for the progression of non-alcoholic steatohepatitis (NASH). Circulating endotoxin levels are elevated in most animal models of diet-induced non-alcoholic fatty liver disease (NAFLD) and NASH. Furthermore, plasma endotoxin levels are significantly higher in NAFLD patients, which is associated with small intestinal bacterial overgrowth and increased intestinal permeability. By improving the gut microbiota environment and restoring gut-barrier functions, probiotics are effective for NASH treatment in animal models. It is also widely known that hepatic fibrosis and suppression of activated hepatic stellate cells (Ac-HSCs) can be attenuated using an angiotensin-II type 1 receptor blocker (ARB). We thus evaluated the effect of combination probiotics and ARB treatment on liver fibrosis using a rat model of NASH. Methods: Fisher 344 rats were fed a choline-deficient/L-amino acid-defined (CDAA) diet for 8 weeks to generate the NASH model. Animals were divided into ARB, probiotics, and ARB plus probiotics groups. Therapeutic efficacy was assessed by evaluating liver fibrosis, the lipopolysaccharide Toll-like receptor (TLR)4 regulatory cascade, and intestinal barrier function. Results: Both probiotics and ARB inhibited liver fibrosis, with concomitant HSC activation and suppression of liver-specific transforming growth factor-β and TLR4 expression. Probiotics reduced intestinal permeability by rescuing zonula occludens-1 disruption induced by the CDAA diet. Angiotensin-II type 1 receptor blocker was found to directly suppress Ac-HSCs. Conclusions: Probiotics and ARB are effective in suppressing liver fibrosis through different mechanisms. Currently both drugs are in clinical use; therefore, the combination of probiotics and ARB is a promising new therapy for NASH.; 博士（医学）・乙第1465号・令和2年9月30日; © 2018 The Japan Society of Hepatology; This is the pre-peer reviewed version of the following article: [https://onlinelibrary.wiley.com/doi/full/10.1111/hepr.13281], which has been published in final form at [https://doi.org/10.1111/hepr.13281]. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions.; identifier:Hepatology research Vol.49 No.3 p.284-295 (2020 Mar); identifier:13866346; identifier:http://ginmu.naramed-u.ac.jp/dspace/handle/10564/3781; identifier:Hepatology research, 49(3): 284-295
• Persistent ID (NDL): info:ndljp/pid/11583359; https://dl.ndl.go.jp/pid/11583359
• Collection: 障害者向け資料
• Collection (Materials For Handicapped People:1): テキストデータ
• Collection (particular): 国立国会図書館デジタルコレクション > デジタル化資料 > 博士論文; https://dl.ndl.go.jp/collections/A00014
• Acquisition Basis: 博士論文（自動収集）
• Date Accepted (W3CDTF): 2020-12-08T06:37:43+09:00
• Format (IMT): application/pdf
• Access Restrictions: 国立国会図書館内限定公開
• Service for the Digitized Contents Transmission Service: 図書館・個人送信対象外
• Availability of remote photoduplication service: 可
• Related Material (URI): https://doi.org/10.1111/hepr.13281
• Periodical Title (URI): http://hdl.handle.net/10564/3781
• Data Provider (Database): 国立国会図書館 : 国立国会図書館デジタルコレクション; https://dl.ndl.go.jp

Table of Contents

2024-05-04 再収集

2024-05-04 再収集

2024-05-04 再収集